Abstracts Archive - Page 2210 of 2605 - ACR Meeting Abstracts

Abstract Number: 323 • 2014 ACR/ARHP Annual Meeting
Anti-Inflammatory Marine Compound, Lyy-B2, Ameliorates Rheumatoid Arthritis through Inhibition of Osteoclast Differentiation
Yen-You Lin¹, Hsin-Pai Lee^1,2, Shi-Ying Huang¹, Han-Chun Hung³, Chien-Wei Feng³, Chun-Hong Chen³, Jui-Hsin Su^4,5, Ping-Jyun Sung^4,5, Jyh-Horng Sheu^1,3, Yen-Hsuan Jean² and Zhi-Hong Wen^1,3, ¹Department of Marine Biotechnology and Resources, Asia-Pacific Ocean Research Center, National Sun Yat-Sen University, Kaohsiung, Taiwan, ²Section of Orthopedic Surgery, Pingtung Christian Hospital, Pingtung, Taiwan, ³Doctoral Degree Program in Marine Biotechnology, National Sun Yat-Sen University, Kaohsiung, Taiwan, ⁴Graduate Institute of Marine Biotechnology, National Dong Hwa University, Pingtung, Taiwan, ⁵Taiwan Coral Research Center, National Museum of Marine Biology & Aquarium, Pingtung, Taiwan
Background/Purpose: Osteoclasts are multinucleated giant cells of macrophage/monocyte lineage, and are believed to play major roles in joint destruction caused by rheumatoid arthritis (RA). Nuclear…
Abstract Number: 322 • 2014 ACR/ARHP Annual Meeting
Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer¹, Rambon Shamilov¹, Caroline Stremnitzer¹, Katie Matthews¹, Michael Fisher¹, William Windsor¹, James Blinn¹, Ellen M. Ginzler³ and Jefferson Tilley¹, ¹Innovimmune Biotherapeutics, Brooklyn, NY, ²SUNY-Downstate Medical Center, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: T helper 17 [TH17] cells and its production of TH17 cytokines IL-17A and IL-17F play a critical role in the pathogenesis of RA and…
Abstract Number: 321 • 2014 ACR/ARHP Annual Meeting
Mutations of Familial Hemophagocytic Lymphohistiocytosis (FHL) Related Genes and Abnormalities of Cytotoxicity function tests in Patients with Macrophage Activation Syndrome (MAS) Occurring in Systemic Juvenile Idiopathic Arthritis (sJIA)
Claudia Bracaglia¹, Elena Sieni², Martina Da Ros², Carmela De Fusco³, Concetta Micalizzi⁴, Valentina Cetica², Benedetta Ciambotti², Maria Luisa Coniglio², Antonella Insalaco⁵, Fabrizio De Benedetti Sr.¹ and Maurizio Arico' Sr.⁶, ¹Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ²Department of Pediatric Hematology-Oncology, Meyer Children’s Hospital, Florence, Italy, ³Department of Pediatric Hematology-Oncology, Pausillipon Children’s Hospital, Naple, Italy, ⁴Department of Pediatric Hematology-Oncology, G. Gaslini Children' s Hospital, Genoa, Italy, ⁵Department of Pediatric Medicine,, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ⁶Istituto Toscano Tumori (I.T.T.), Florence, Italy
Background/Purpose: MAS is a severe complication of rheumatic diseases, mostly sJIA. Clinical and laboratory features are similar to those of FHL resulting from mutations in…
Abstract Number: 320 • 2014 ACR/ARHP Annual Meeting
Autoantibodies in Juvenile Systemic Sclerosis
Katharine Moore^1,2, J. Lee Nelson^3,4, Marvin J. Fritzler⁵, Marisa S. Klein-Gitelman⁶, Ann M. Reed⁷, Tzielan C. Lee⁸ and Anne M. Stevens^1,9, ¹Pediatrics, University of Washington, Seattle, WA, ²Pediatric Rheumatology, Seattle Children's Hospital, Seattle, WA, ³University of Washington, Seattle, WA, ⁴Fred Hutchinson Cancer Research Center, Seattle, WA, ⁵Mitogen Advanced Diagnostics Laboratory, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁷Rheumatology, Mayo Clinic, Rochester, MN, ⁸Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: There are no known biomarkers for organ involvement, response to therapy, or prognosis in juvenile systemic sclerosis (jSSc). In adults with systemic sclerosis, a…
Abstract Number: 319 • 2014 ACR/ARHP Annual Meeting
Systemic Juvenile Idiopathic Arthritis and Exposure to Fine Particulate Air Pollution
Andrew S. Zeft¹, Sampath Prahalad², Rayfel Schneider³, Alexei Grom⁴, Fatma Dedeoglu⁵, Pamela F. Weiss⁶, Carter Mix⁷ and C. Arden Pope⁸, ¹Pediatrics, Rheumatology, The Cleveland Clinic, Cleveland, OH, ²Emory University, Atlanta, GA, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵on behalf of CARRAnet Investigators, Palo Alto, CA, ⁶Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁷Brigham Young University, Provo, UT, ⁸Economics, Brigham Young University, Provo, UT
Background/Purpose: Environmental factors are understood to play a pathogenic role in the etiology of Systemic Onset Juvenile Idiopathic Arthritis (SJIA). Fine particulate matter (aerodynamic diameter…
Abstract Number: 338 • 2014 ACR/ARHP Annual Meeting
Bombina Variegate peptide8/Prokineticin 2: A Novel Arthritis-Inducible Chemokine
Haruyasu Ito, Ken Yoshida, Kentaro Noda and Daitaro Kurosaka, Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by the joint destruction. Chemokines play important roles as monocyte and neutrophil recruiters in RA.…
Abstract Number: 337 • 2014 ACR/ARHP Annual Meeting
Effect of Etanercept on Endothelial Dysfunction in Rat Adjuvant-Induced Arthritis
Perle Totoson¹, Katy Maguin-Gaté¹, Daniel Wendling² and Céline Demougeot¹, ¹EA 4267 « Fonctions et Dysfonctions Epithéliales » , Faculté de Médecine-Pharmacie, Besançon, France, ²Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose Growing evidence indicate that Rheumatoid Arthritis (RA)-associated increase in cardiovascular risk is secondary to the presence of endothelial dysfunction (ED). Although Tumor Necrosis Factor…
Abstract Number: 336 • 2014 ACR/ARHP Annual Meeting
The Additive Inflammatory in Vivo and in Vitro Effects of Thymic Stromal Lymphopoietin (TSLP) and IL-7 in Arthritis Underscore the Therapeutic Rationale for blockade of Their Common Receptor Subunit
M.R. Hillen^1,2, S.A.Y. Hartgring^1,2, T.R.D.J. Radstake^2,3, C.E. Hack^1,2, F.P.J.G. Lafeber¹ and J.a.G. van Roon^1,2, ¹Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ²Laboratory for Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose Interleukin (IL)-7 and thymic stromal lymphopoietin (TSLP) are cytokines that signal through the IL-7Ra subunit and play proinflammatory roles in experimental arthritis and rheumatoid…
Abstract Number: 335 • 2014 ACR/ARHP Annual Meeting
Interleukin-33 Suppresses Experimental Arthritis through Promoting Foxp3⁺ Regulatory T-Cells and Type-2 Immune Responses in Mice
Jerome Biton¹, Allan Thiolat¹, Sara khaleghparast Athari¹, Delphine Lemeiter², Roxanne Herve¹, Patrice Decker¹, Jean-Philippe Girard³, Stephane Roga³, André Herbelin⁴, Anais Levascot⁴, Marie-Christophe Boissier² and Natacha Bessis¹, ¹INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, ²INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France, ³Centre National de la Recherche Scientifique, Institut de Pharmacologie, dUniversité de Toulouse, Université Paul Sabatier, Institut de Pharmacologie et de Biologie Structurale et de Biologie Structurale, toulouse, France, ⁴INSERM U1082, Pôle Biologie Santé,, poitiers, France
Background/Purpose Interleukin (IL)-33 is a new member of the IL-1 family that exerts pleiotropic activities in innate and adaptive immunity. With its receptor ST2, they…
Abstract Number: 318 • 2014 ACR/ARHP Annual Meeting
HLA-B27 Subtypes in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis
Rajni Srivastava¹, Shikha Agnihotry², Rakesh Aggarwal³ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Bioinformatics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: HLA-B27 has a high degree of genetic polymorphism, with more than 105 known subtypes. Enthesitis Related Arthritis (ERA) is most common form of Juvenile Idiopathic Arthritis…
Abstract Number: 303 • 2014 ACR/ARHP Annual Meeting
Predicting Chronic Pain in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Prospective Study
Amir Rashid¹, Kate Holliday¹, Lis Cordingley¹, Roberto Carrasco¹, Bo Fu², Helen E. Foster³, Eileen Baildam⁴, Alice Chieng⁵, Joyce Davidson⁶, Lucy Wedderburn⁷, Kimme Hyrich⁸ and Wendy Thomson⁹, ¹Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ²Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, ³Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁵Paediatric Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁶Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁷Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ⁸Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁹Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
· Background/Purpose: Pain is the most common symptom of JIA and has been associated with disease activity. However, disease activity has only accounted for a…
Abstract Number: 302 • 2014 ACR/ARHP Annual Meeting
Qualitative Assessment of Important Long-Term Outcomes in Juvenile Idiopathic Arthritis
Melissa L. Mannion¹, Michelle Williams², Gerald McGwin Jr.³, Kenneth G. Saag⁴ and Timothy Beukelman¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose JIA is not a childhood disease, but a chronic disease that begins in childhood. Long term outcomes that physicians and patients care most about…
Abstract Number: 301 • 2014 ACR/ARHP Annual Meeting
Pregnancies in Females with Juvenile Idiopathic Arthritis (JIA) Who Were Exposed to Biologics and/or Methotrexate – Results from a Biologic Register
Katrin Stüdemann¹, Martina Niewerth¹, Jens Klotsche¹, Angela Zink², Gerd Horneff³ and Kirsten Minden^1,4, ¹Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Chidlrens´ hospital, Charité University Medicine, Berlin, Germany
Background/Purpose JIA often continues into adult life and affects about 1 in 1,000 people of childbearing age. Little is known about the impact of JIA…
Abstract Number: 300 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Joint Count in Juvenile Idiopathic Arthritis: The Reliability of a Mannequin Format
Maryanne Dijkstra¹, Janneke Anink¹, Philomine A. van Pelt^1,2, Johanna M.W. Hazes² and Lisette W.A. van Suijlekom-Smit¹, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a common chronic disease, requiring regular monitoring. Patient-reported outcomes can assist monitoring, may promote patient self-management and can be…
Abstract Number: 299 • 2014 ACR/ARHP Annual Meeting
A Controlled Trial of Intra-Articular Corticosteroids with or without Methotrexate in Oligoarticular Juvenile Idiopathic Arthritis
Angelo Ravelli^1,2, Giulia Bracciolini³, Sergio Davì³, Angela Pistorio⁴, Alessandro Consolaro⁴, Sara Verazza³, Bianca Lattanzi⁴, Giovanni Filocamo⁴, Sara Dalprà³, Maurizio Gattinara⁵, Valeria Gerloni⁶, Antonella Insalaco⁷, Fabrizio De Benedetti Sr.⁸, Adele Civino⁹, Luciana Breda¹⁰, Loredana Lepore¹¹, Maria Cristina Maggio¹², Franco Garofalo¹³, Silvia Magni-Manzoni¹⁴, Donato Rigante¹⁵, Antonella Buoncompagni⁴, Marco Gattorno⁴, Clara Malattia¹⁶, Stefania Viola¹⁷, Paolo Picco⁴, Nicolino Ruperto¹⁸ and Alberto Martini¹, ¹Istituto Giannina Gaslini and University of Genova, Genova, Italy, ²University of Genova, Genova, Italy, ³Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ⁴Istituto Giannina Gaslini, Genova, Italy, ⁵Pediatric Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁶Pediatric Rheumatology Unit, Department of Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁷Department of Pediatric Medicine,, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ⁸Clinica Pediatrica, Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁹Ospedale Cardinale G. Panico, Tricase, Italy, ¹⁰Ospedale Policlinico, Chieti, Italy, ¹¹Istituto Burlo Garofolo, Trieste, Italy, ¹²University of Palermo, Palermo, Italy, ¹³Ospedale degli Infermi, Biella, Italy, ¹⁴Ospedale Pediatrico Bambino Gesù, Roma, Italy, ¹⁵Pediatrics, Università Cattolica Sacro Cuore, Rome, Italy, ¹⁶Claramalattia@Ospedale-Gaslini, Istituto Giannina Gaslini and University of Genova, Genova, Italy, ¹⁷Istituto G. Gaslini, Istituto Giannina Gaslini, Genova, Italy, ¹⁸Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose In contrast with the numerous randomized controlled trials conducted in polyarticular or systemic juvenile idiopathic arthritis (JIA), little evidence-based information is available for oligoarticular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].